Study of IMC-P115C in Advanced PRAME-Positive Cancers
← catalyst calendarNCT07156136 · readout in 407 d
Sponsored by Immunocore Ltd (industry) · IMCR — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
140estimated
Sites
13
Countries
Australia, France, Italy +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-07 | actual | When the study began enrolling |
| Primary completion | 2027-09-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-08-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- PRAME Positive
- Cancer
- HLA-A*02:01-positive
Intervention
- Drug: IMC-P115C
Primary outcomes
what the primary-completion date above is the date OFPercentage of participants with dose-limiting toxicities (DLT)
measured Up to ~16 months
Percentage of participants with adverse events (AE)
measured Up to ~16 months
Percentage of participants with serious adverse events (SAE)
measured Up to ~16 months
Percentage of participants with a dose interruption, reduction, or discontinuation
measured Up to ~16 months
Permalink · IMCR's whole pipeline · Catalyst calendar · Every registered study · What changed